Clinical Trial Update: A Trial Study of SGN-00101 in Treating Pediatric Patients With Recurrent Respiratory Papillomatosis [Phase 2]

View source ↗

Summary

This entry reports the completion of a Phase 2 clinical trial evaluating SGN-00101 in pediatric patients with recurrent respiratory papillomatosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Papillomatosis

Drugs mentioned

• SGN-00101

Snippet

Sponsor: Nventa Biopharmaceuticals Corporation | Conditions: Papilloma, Recurrent Respiratory Papillomatosis | Phase 2 | Status: COMPLETED